SVB Leerink Downgrades Moderna (MRNA) to Underperform

SVB Leerink analyst Mani Foroohar downgraded Moderna (NASDAQ: MRNA) from Market Perform to Underperform with a price target of $93.00 (from $111.00).

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $147.57 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades BioMerieux (BIM:FP) (BMXMF) to Underweight
• Morgan Stanley Upgrades Sonova Holding AG (SOON:SW) (SONVY) to Equalweight
• Flat Glass Group Co Ltd (6865:HK) (FGSGF) PT Lowered to HK$7 at Citi